Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898613 | 1.00 | MAPK14 (0.46) | MAPK14CMA1AHRPIM1MEN1 | |
| SCHEMBL15579296 | 0.92 | CMA1 (0.49) | MAPK14CMA1AHRPIM1MEN1 | |
| SCHEMBL31079938 | 0.92 | CMA1 (0.49) | MAPK14CMA1AHRPIM1MEN1 | |
| SCHEMBL30954711 | 0.88 | PGR (0.47) | MAPK14MEN1KMT2ABACE1PGR | |
| SCHEMBL2075283 | 0.85 | CMA1 (0.46) | MAPK14CMA1AHRPIM1MEN1 | |
| SCHEMBL1224056 | 0.85 | MAPK14 (0.46) | MAPK14CMA1AHRPIM1MEN1 | |
| SCHEMBL1233730 | 0.84 | PGR (0.46) | MAPK14CMA1AHRPGR | |
| SCHEMBL13650357 | 0.83 | MAPK14 (0.53) | MAPK14PGR | |
| SCHEMBL30898646 | 0.83 | CMA1 (0.44) | MAPK14CMA1AHRPIM1MEN1 | |
| SCHEMBL16440215 | 0.83 | BACE1 (0.50) | MAPK14CMA1AHRPIM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020192652-A1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | 上海华汇拓医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| US-8772288-B2 | Substituted spiro[cycloalkyl-1,3′-indo]-2′(1′H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2014-07-08 | — | — | US | disclosed |
| EP-2280943-B1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDO]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2013-11-06 | — | — | EP | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| US-8450341-B2 | Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors | ALMIRALL, S.A. (ES) | 2013-05-28 | — | — | US | disclosed |
| EP-2280953-B1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-03-03 | — | — | US | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2011-02-24 | — | — | US | disclosed |
| EP-2280953-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| EP-2280943-A1 | NEW SUBSTITUTED SPIROÝCYCLOALKYL-1,3'-INDOL¨-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | Almirall, S.A. (ES) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009132774-A1 | NEW SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P39 MITOGEN-ACTIVATED KINASE INHIBITORS | ALMIRALL, S. A. (ES) | 2009-11-05 | — | — | WO | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| EP-2113503-A1 | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124692-A1 | NEW SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS. | ALMIRALL, S.A. (ES) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
| EP-2108641-A1 | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors | Laboratorios Almirall, S.A. (ES) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046097-A1 | SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAPKAPK2, MAPK7 | MAPK14 15/4885CMA1 1772/4885AHR 1195/4885 |
| US-20110053936-A1 | SUBSTITUTED SPIRO[CYCLOALKYL-1,3'-INDOL]-2'(1'H)-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAPK14 25/4885CMA1 1844/4885AHR 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.